Navigation Links
CryoLife Announces Release Date and Teleconference Call Details for 2011 Second Quarter Financial Results
Date:7/20/2011

ATLANTA, July 20, 2011 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device Company focused on cardiac and vascular surgery, announced today that 2011 second quarter financial results will be released on Thursday, July 28, 2011.  On that day, the Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and chief executive officer of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m.  A replay of the teleconference will be available July 28 through August 4 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.  The account number for the replay is 244 and the conference number is 376045.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of the right ventricular outflow tract (RVOT), which is a surgery commonly performed in children with congenital heart defects, such as Tetralogy of Fallot, Truncus Arteriosus, and Pulmonary Atresia. CryoPatch SG is distributed in three anatomic configurations: pulmonary hemi-artery, pulmonary trunk, and pulmonary branch.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair and was recently approved in Japan for use in the repair of aortic dissections.  CryoLife's BioFoam™ Surgical Matrix is CE marked in the European Community for use as an adjunct in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community. CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of cardiovascular disease and devices that treat severe angina.  Its market leading FDA-approved Holmium: YAG laser system and single use fiber-optic delivery systems are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR). 

For additional information about the company, visit CryoLife's Web site:  http://www.cryolife.com.Contacts:CryoLifeThe Ruth GroupD. Ashley Lee

Nick Laudico / Zack KubowExecutive Vice President, Chief Financial Officer and

646-536-7030 / 7020Chief Operating Officer

nlaudico@theruthgroup.comPhone: 770-419-3355

zkubow@theruthgroup.com
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
2. CryoLife Receives FDA Approval to Begin U.S. Clinical Trial for BioFoam(R)
3. CryoLife Reports Record Quarterly Revenues of $28.2 Million
4. CryoLife to Present at Upcoming Investor Conferences in New York
5. CryoLife to Present at 21st Annual Piper Jaffray Health Care Conference
6. CryoLife Provides Initial 2010 Financial Guidance
7. CryoLife Enters into Worldwide Distribution and Manufacturing Agreements with Starch Medical for Novel Hemostatic Agent
8. CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive
9. CryoLife Announces Release Date and Teleconference Call Details for 2010 Third Quarter Financial Results
10. CryoLife Begins Distribution of Blood-Clotting Agent PerClot® in Europe
11. CryoLife to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... , July 10, 2017 The Institute ... test methods, is the recipient of a VITROCELL® inhalation ... PETA International Science Consortium. The device, which is designed ... to expose human lung cells to airborne test materials ... will use the VITROCELL® system for testing combustible tobacco ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Sharon Kleyne, host of the nationally ... on VoiceAmerica sponsored by Nature’s Tears® EyeMist® recently talked on the air about an ... China. , The article by Zidor Aldama described the situation in which Chinese children ...
(Date:7/24/2017)... CUMBERLAND, PA (PRWEB) , ... July 24, 2017 ... ... by 2030, today CURE announced that they have enrolled over 100,000 children in ... 158,000 afflicted children born every year in areas where treatment is limited or ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced Dermatology, P.C. ... York, (516) 784-5858. The office opened earlier this summer and is currently accepting ... Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and medical director Dr. ...
(Date:7/24/2017)... ... ... The Center for Addiction Recovery Training (CART), the training ... Multiple Pathways of Recovery Conference on October 23-26, 2017. This year, the conference ... principle – a belief in multiple pathways of recovery, aims to bring many ...
(Date:7/23/2017)... CANADA (PRWEB) , ... July 23, 2017 , ... ... of single sport specialization is critical, say researchers presenting their work today at ... Toronto, Canada. , “Our study is the first one to prospectively document ...
Breaking Medicine News(10 mins):